CN115943163A - 位点特异性Notch激活分子及其用途 - Google Patents

位点特异性Notch激活分子及其用途 Download PDF

Info

Publication number
CN115943163A
CN115943163A CN202180046740.7A CN202180046740A CN115943163A CN 115943163 A CN115943163 A CN 115943163A CN 202180046740 A CN202180046740 A CN 202180046740A CN 115943163 A CN115943163 A CN 115943163A
Authority
CN
China
Prior art keywords
antigen
binding
antibody
binding molecule
notch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180046740.7A
Other languages
English (en)
Chinese (zh)
Inventor
黄振宁
类家庆直
村松弘康
井川智之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN115943163A publication Critical patent/CN115943163A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202180046740.7A 2020-06-30 2021-06-30 位点特异性Notch激活分子及其用途 Pending CN115943163A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020112553 2020-06-30
JP2020-112553 2020-06-30
PCT/JP2021/024655 WO2022004761A1 (en) 2020-06-30 2021-06-30 Site specific notch-activating molecule and uses thereof

Publications (1)

Publication Number Publication Date
CN115943163A true CN115943163A (zh) 2023-04-07

Family

ID=79316658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180046740.7A Pending CN115943163A (zh) 2020-06-30 2021-06-30 位点特异性Notch激活分子及其用途

Country Status (6)

Country Link
US (1) US20230383011A1 (https=)
EP (1) EP4172210A4 (https=)
JP (2) JP7808039B2 (https=)
CN (1) CN115943163A (https=)
TW (2) TW202547877A (https=)
WO (1) WO2022004761A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121490066A (zh) * 2025-12-31 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 重组蛋白制剂anxa2作为notch激动剂的新应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024336361A1 (en) * 2023-09-08 2026-04-23 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4365583B2 (ja) 2000-09-22 2009-11-18 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
AR063494A1 (es) * 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
JP2012056934A (ja) * 2010-09-13 2012-03-22 Chiba Univ 抗ノッチ１アゴニスト抗体を含む組織再生治療剤及び該抗体を使用する組織再生治療方法
CN112812184A (zh) * 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
JP2013231018A (ja) * 2012-05-02 2013-11-14 Juntendo 腎疾患治療薬
US20180320135A1 (en) * 2015-11-06 2018-11-08 The Board Of Trustees Of The University Of Illinois Ox40l-jagged-1 chimeric polypeptides and uses thereof
US11261250B2 (en) * 2016-07-22 2022-03-01 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions
US11613567B2 (en) * 2017-03-24 2023-03-28 Ohio State Innovation Foundation Modulators of notch signaling and methods of use thereof
EP4004040A4 (en) * 2019-07-29 2023-08-16 Fred Hutchinson Cancer Center METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROOM ENVIRONMENTS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121490066A (zh) * 2025-12-31 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 重组蛋白制剂anxa2作为notch激动剂的新应用

Also Published As

Publication number Publication date
EP4172210A4 (en) 2024-10-16
WO2022004761A1 (en) 2022-01-06
EP4172210A1 (en) 2023-05-03
TW202216775A (zh) 2022-05-01
TW202547877A (zh) 2025-12-16
JP7808039B2 (ja) 2026-01-28
US20230383011A1 (en) 2023-11-30
JP2026010057A (ja) 2026-01-21
JP2023530797A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
KR102505383B1 (ko) Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용
TWI770917B (zh) 密連蛋白６靶向多特異性抗原結合分子及其用途
WO2021200896A1 (en) Immune activating multispecific antigen-binding molecules and uses thereof
KR102747409B1 (ko) 암의 치료에 이용하기 위한 세포 상해 유도 치료제
JP2026010057A (ja) 部位特異的Ｎｏｔｃｈ活性化分子およびその使用
JP2023537553A (ja) ワンアームド抗原結合分子およびその使用
HK40082572A (en) Site specific notch-activating molecule and uses thereof
HK40076266A (en) Claudin-6 targeting multispecific antigen binding molecules and uses thereof
HK40076462B (zh) 靶向 dll3 的多特异性抗原结合分子及其用途
HK40076462A (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
HK40074344A (en) Immune activating multispecific antigen binding molecules and uses thereof
EA047044B1 (ru) Таргетирующие клаудин-6 мультиспецифические антигенсвязывающие молекулы и их применения
EA049685B1 (ru) Таргетирующие dll3 мультиспецифические антигенсвязывающие молекулы и их применения
HK40085740A (en) One-armed antigen-binding molecules and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082572

Country of ref document: HK